Sepsis Upregulates CD14 Expression in a MyD88-Dependent and Trif-Independent Pathway

ABSTRACT An overwhelming immune response, particularly from macrophages, plays a critical role in survival and organ damage in sepsis patients. Toll-like receptors (TLRs) are important receptors to recognize the conserved motifs expressed by invading bacteria. The TLRs except TLR3 signal via a MyD88-dependent pathway. TLR3 uses a TRIF-dependent pathway, while TLR4 uses both MyD88 and TRIF-dependent pathways. Previous studies indicated that CD14 was necessary for TLRs-dependent production of pro-inflammatory cytokines. Blocking CD14 protected against the deleterious systemic inflammatory response associated with sepsis. The aim of this study was to determine the signaling pathway of TLR activation-induced CD14 expression in models of polymicrobial sepsis and in peritoneal macrophages. We found that CD14 expression was upregulated in the lung, liver, and kidney of septic mice induced by cecal ligation puncture. In cultured peritoneal macrophages, specific agonists for all TLRs, except for TLR3, increased CD14 expression. Lipopolysaccharide-induced upregulation of CD14 was abolished in peritoneal macrophages from MyD88 KO mice but increased in TRIF inhibitor, resveratrol pretreated wild-type macrophages. Moreover, MyD88 KO, but not TRIF KO mice, showed a decreased CD14 expression in the tissue of septic mice, which was associated with a strongly attenuated inflammatory response and increased survival rate. These data suggest that a MyD88-dependent and TRIF-independent pathway of TLR is activated in upregulating CD14 expression under septic conditions. This study deciphers a critical cross-talk between TLRs and CD14.

[1]  A. Mencacci,et al.  Diagnostic accuracy of presepsin (sCD14-ST) and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis. , 2016, Journal of medical microbiology.

[2]  T. Billiar,et al.  WISP1-αvβ3 integrin signaling positively regulates TLR-triggered inflammation response in sepsis induced lung injury , 2016, Scientific Reports.

[3]  Lixin Xie,et al.  The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis , 2015, Critical Care.

[4]  L. Moldawer,et al.  TRIF-Dependent Innate Immune Activation Is Critical for Survival to Neonatal Gram-Negative Sepsis , 2015, The Journal of Immunology.

[5]  T. Roger,et al.  Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases , 2013, Front. Immunol..

[6]  B. C. Hellerud,et al.  Systemic CD14 Inhibition Attenuates Organ Inflammation in Porcine Escherichia coli Sepsis , 2013, Infection and Immunity.

[7]  K. Wilhelmsen,et al.  Alveolar Macrophages and Toll-like Receptor 4 Mediate Ventilated Lung Ischemia Reperfusion Injury in Mice , 2012, Anesthesiology.

[8]  K. Schesser,et al.  Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity , 2011, The Journal of experimental medicine.

[9]  Yan Li,et al.  MyD88 and Trif Signaling Play Distinct Roles in Cardiac Dysfunction and Mortality during Endotoxin Shock and Polymicrobial Sepsis , 2011, Anesthesiology.

[10]  J. Colinge,et al.  TLR 2 and CD14 Mediate Innate Immunity and Lung Inflammation to Staphylococcal Panton–Valentine Leukocidin In Vivo , 2011, The Journal of Immunology.

[11]  P. Pronovost,et al.  Long-term mortality and quality of life in sepsis: A systematic review* , 2010, Critical care medicine.

[12]  Mauro M. Teixeira,et al.  Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis , 2009, Proceedings of the National Academy of Sciences.

[13]  G. Plitas,et al.  Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis , 2008, The Journal of experimental medicine.

[14]  R. Hotchkiss,et al.  Deletion of MyD88 markedly attenuates sepsis‐induced T and B lymphocyte apoptosis but worsens survival , 2008, Journal of leukocyte biology.

[15]  山本 雅裕.  Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway , 2006 .

[16]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[17]  P. Tobias,et al.  Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. , 2006, Immunity.

[18]  S. Akira,et al.  The MyD88-Dependent, but Not the MyD88-Independent, Pathway of TLR4 Signaling Is Important in Clearing Nontypeable Haemophilus influenzae from the Mouse Lung1 , 2005, The Journal of Immunology.

[19]  S. Akira,et al.  Specific Inhibition of MyD88-Independent Signaling Pathways of TLR3 and TLR4 by Resveratrol: Molecular Targets Are TBK1 and RIP1 in TRIF Complex1 , 2005, The Journal of Immunology.

[20]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[21]  K. Tracey,et al.  The "cytokine profile": a code for sepsis. , 2005, Trends in molecular medicine.

[22]  J. Bakker,et al.  CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)* , 2004, Critical care medicine.

[23]  Shizuo Akira,et al.  Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-β (TRIF) Associates with TNF Receptor-Associated Factor 6 and TANK-Binding Kinase 1, and Activates Two Distinct Transcription Factors, NF-κB and IFN-Regulatory Factor-3, in the Toll-Like Receptor Signaling 1 , 2003, The Journal of Immunology.

[24]  R. Vabulas,et al.  Cutting Edge: Myeloid Differentiation Factor 88 Deficiency Improves Resistance Against Sepsis Caused by Polymicrobial Infection1 , 2002, The Journal of Immunology.

[25]  J. Pribble,et al.  IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis , 2001, Journal of endotoxin research.

[26]  S. Akira,et al.  Synergy and Cross-Tolerance Between Toll-Like Receptor (TLR) 2- and TLR4-Mediated Signaling Pathways1 , 2000, The Journal of Immunology.

[27]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[28]  R. Ulevitch,et al.  Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Su,et al.  Tissue coexpression of LBP and CD14 mRNA in a mouse model of sepsis. , 1998, The Journal of surgical research.

[30]  A. Tomasz,et al.  CD14 is a pattern recognition receptor. , 1994, Immunity.

[31]  R. Landmann,et al.  Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages , 1991, Journal of cellular biochemistry.

[32]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[33]  S. Akira,et al.  TLR signaling. , 2006, Cell death and differentiation.

[34]  J. Kamps,et al.  Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. , 2005, Journal of hepatology.